Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

July 10, 2024

Study Completion Date

July 10, 2024

Conditions
Frontal Fibrosing AlopeciaLichen Planopilaris of Scalp
Interventions
DRUG

Tofacitinib 5 MG

Participants in the research will receive oral Tofacitinib medication with a dosage of 5 mg, twice a day, for 12 weeks. They will be scheduled to come for follow-up every 4 weeks throughout the 12-week period, and will continue to be followed up for 4 weeks after stopping the medication. The total duration of the research will be 16 weeks. The purpose is to evaluate the effectiveness and safety of the medication.

Trial Locations (1)

10400

Hair and Nail center, Institute of Dermatology, Bangkok

All Listed Sponsors
lead

Institute of Dermatology, Thailand

OTHER_GOV

NCT06202560 - Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study | Biotech Hunter | Biotech Hunter